OSI-7904L

OSI-7904L is a liposomal formulation of a tetrahydrofuran antineoplastic agent. It is a type of chemotherapy drug that is used in the treatment of various types of cancer. OSI-7904L is designed to target and kill cancer cells, while minimizing damage to healthy cells.

Mechanism of Action

OSI-7904L works by inhibiting the synthesis of DNA in cancer cells, preventing them from dividing and growing. The drug is encapsulated in liposomes, which are small, spherical vesicles made of lipid bilayers. These liposomes help to deliver the drug directly to the cancer cells, reducing the impact on healthy cells and potentially reducing side effects.

Clinical Trials

OSI-7904L has been studied in a number of clinical trials for its effectiveness in treating various types of cancer. These trials have shown promising results, with some patients experiencing a reduction in tumor size and improved survival rates. However, like all chemotherapy drugs, OSI-7904L can have serious side effects, and its use must be carefully monitored by a healthcare professional.

Side Effects

Common side effects of OSI-7904L include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include neutropenia, a condition characterized by a low number of neutrophils, a type of white blood cell that helps fight infection. Patients receiving OSI-7904L may also experience thrombocytopenia, a condition characterized by a low number of platelets, which are needed for blood clotting.

See Also

• Chemotherapy
• Clinical trial
• Cancer
• Liposome
• Tetrahydrofuran

This Chemotherapy related article is a stub. You can help WikiMD by expanding it.